Blauwendraat, C., Nalls, M
Some of those may be expected, such as less hunger and fewer cravings
Semaglutide (marketed under brand names Ozempic and Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist medication
Under conditions of chronic hypophagia, metabolic adaptation increasingly depends on maintaining proportionality between oxidative demand and substrate-supported regenerative capacity
While there is good reason to be hopeful that generic versions will be available in coming years, for now the out-of-pocket costs make long-term use inaccessible for most people
Ozempic for weight loss is intended to be a long-term treatment, so when used safely, patients will likely take over a year before they are able to reach their goal weight